MedTrace Logo

Automated Insulin Delivery in Type 1 Diabetes Complicated by Gastroparesis

NCT05795309 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-09-13

No results posted yet for this study

Summary

This is a staggered randomised controlled trial that aims to assess the impact of an automated insulin delivery (AID) system on glucose, gastrointestinal and patient-reported outcomes.

Conditions

Interventions

DEVICE

Hybrid Automated Insulin Delivery

Consists of an insulin pump and real-time continuous glucose monitoring (CGM)

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Nick Oliver · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-16
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05795309 on ClinicalTrials.gov